Loading company…
Daejeon-based Orum Therapeutics develops cell-penetrating antibodies to treat genetic diseases and cancers.
Founded in 2016, the company raised KRW 50 billion in a February 2025 IPO, selling 2.5 million shares at KRW 20,000 each on the KOSDAQ, below the expected KRW 24,000 to KRW 30,000 range. Proceeds are intended for research and development and general operating costs from 2025, alongside existing cash and expected technology-licensing revenue.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in